Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System.

ABSTRACT: There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were hospitalized or died. The 43% observed risk reduction with bebtelovimab was not statistically significant (P = 0.14).

SUBMITTER: Dryden-Peterson S 

PROVIDER: S-EPMC9620388 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature